Farringdon Capital’s Biogen BIIB Stock Holding History

Farringdon Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,054	Closed	-$1.66M	–	220
2026 Q1	$1.66M	Buy	+9,054	New	+$1.67M	0.36%	91

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Farringdon Capital's BIIB Position: Q2 2026 in Review

Farringdon Capital sold out of Biogen (BIIB) in Q2 2026, closing a stake of 9,054 shares — an estimated $1.66M sold.

Farringdon Capital first reported a position in BIIB in Q1 2026 and held it in 1 quarter. The position peaked at $1.66M in Q1 2026. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Farringdon Capital reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
Farringdon Capital sold 9,054 Biogen shares in Q2 2026, an estimated $1.66M.
Farringdon Capital first reported a position in Biogen in Q1 2026 and held it in 1 quarter.
Farringdon Capital's Biogen position peaked at $1.66M in Q1 2026.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Farringdon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.